Antioxidant enzyme profile of two clinical isolates of Entamoeba histolytica varying in sensitivity to antiamoebic drugs

Figure 1 mRNA expression and activity levels of thioredoxin reductase in clinical isolate 980 of Entamoeba histolytica during treatment with antiamoebic drugs. A: Graphical representation of densitometric data from semiquantitative RT-PCR analysis of Thioredoxin reductase in clinical isolate 980. Untreated (980 N), auranofin treated (980 A) and metronidazole treated (980 M). Densitometric values are expressed as percent after normalizing with 18S rRNA. Each pair of columns show the data for untreated and treated isolate. Data are mean ± SE of three independent experiments. ^aP < 0.05 in case of auranofin treatment; B: Activity of thioredoxin reductase in clinical isolate 980, untreated (980 N), auranofin treated (980 A) and metronidazole treated (980 M). Each pair of columns show the enzyme activity in units/mg protein, for the treated and untreated isolate; C: Representative gel image: 980 N: Untreated isolate; 980 A: Auranofin treated; 980 M: Metronidazole treated. M: Marker; +ve C: HM-1: IMSS cDNA used as +ve control; -ve C: cDNA from blank medim used as -ve control; TrxR: Thioredoxin reductase; E. histolytics: Entamoeba histolytica.